Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 3/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | MPO | P05164 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.60 |
| ▸ | ACE | P12821 | 3/20 | 0.59 |
| ▸ | ECE1 | P42892 | 6/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28334124 | 1.00 | CTSC (0.67) | CTSCMEN1KMT2AKDM4ELMNA | |
| SCHEMBL9447263 | 1.00 | CTSC (0.67) | CTSCMEN1KMT2AKDM4ELMNA | |
| SCHEMBL30051770 | 0.98 | CTSC (0.65) | CTSCMEN1KMT2AKDM4ELMNA | |
| SCHEMBL30052009 | 0.97 | CTSC (0.64) | CTSCMEN1KMT2AKDM4ELMNA | |
| SCHEMBL30051220 | 0.95 | CTSC (0.62) | CTSCMEN1KMT2AKDM4ELMNA | |
| SCHEMBL30051511 | 0.95 | CTSC (0.64) | CTSCMEN1KMT2AKDM4ELMNA | |
| SCHEMBL30051910 | 0.94 | CTSC (0.61) | CTSCMEN1KMT2AKDM4ELMNA | |
| SCHEMBL30051560 | 0.93 | CTSC (0.60) | CTSCMEN1KMT2AKDM4ELMNA | |
| SCHEMBL30051343 | 0.93 | ERAP2 (0.63) | CTSCMEN1KMT2AACEECE1 | |
| SCHEMBL30053106 | 0.93 | CTSC (0.69) | CTSCMEN1KMT2AKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695413-A1 | PHOSPHONOALANINE OLIGOPEPTIDES AND METHODS OF MAKING AND USE THEREOF | Ohio State Innovation Foundation (US) | 2026-02-18 | — | — | EP | claimed |
| WO-2024216031-A1 | PHOSPHONOALANINE OLIGOPEPTIDES AND METHODS OF MAKING AND USE THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2024-10-17 | — | — | WO | claimed |
| EP-3971169-B1 | METHOD FOR PRODUCING, IN A CELL, A PROTEIN OR A POLYPEPTIDE COMPRISING A TETRAZINE AMINO ACID | UNIV OREGON STATE (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4719391-A2 | TRIPLE KINASE INHIBITORS | Unogen Biotech Ltd. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260085050-A1 | TRIPLE KINASE INHIBITORS | UNOGEN BIOTECH LTD (US) | 2026-03-26 | — | — | US | disclosed |
| EP-3604503-B1 | ADDITIVE FOR UNDIFFERENTIATION MAINTAINING MEDIUM | AJINOMOTO KK (JP) | 2026-03-18 | — | — | EP | disclosed |
| EP-4695413-A1 | PHOSPHONOALANINE OLIGOPEPTIDES AND METHODS OF MAKING AND USE THEREOF | Ohio State Innovation Foundation (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260028320-A1 | REAGENTS AND METHODS FOR BIOORTHOGONAL LABELING OF BIOMOLECULES IN LIVING CELLS | OREGON STATE UNIVERSITY (US) | 2026-01-29 | — | — | US | disclosed |
| US-20250270512-A1 | ADDITIVE FOR UNDIFFERENTIATION MAINTAINING MEDIUM | AJINOMOTO CO., INC. (JP) | 2025-08-28 | — | — | US | disclosed |
| US-20250262216-A1 | THERAPEUTIC USES OF MACROCYCLIC COMPOUNDS | TURNING POINT THERAPEUTICS INC (US) | 2025-08-21 | — | — | US | disclosed |
| EP-3971169-A1 | METHOD FOR PRODUCING, IN A CELL, A PROTEIN OR A POLYPEPTIDE COMPRISING A TETRAZINE AMINO ACID | Oregon State University (US) | 2022-03-23 | — | — | EP | disclosed |
| US-20200040308-A1 | ADDITIVE FOR UNDIFFERENTIATION MAINTAINING MEDIUM | AJINOMOTO CO., INC. (JP) | 2020-02-06 | — | — | US | disclosed |
| EP-3604503-A1 | ADDITIVE FOR UNDIFFERENTIATION MAINTAINING MEDIUM | Ajinomoto Co., Inc. (JP) | 2020-02-05 | — | — | EP | disclosed |
| CN-110494559-A | It maintains to use culture medium additive undifferentiatedly | AJINOMOTO KK | 2019-11-22 | — | — | CN | disclosed |
| US-20110262962-A1 | METHOD FOR PRODUCING PEPTIDES | AJINOMOTO CO., INC. (JP) | 2011-10-27 | — | — | US | disclosed |
| US-20070292916-A1 | MUTANT PROTEIN HAVING THE PEPTIDE-SYNTHESIZING ACTIVITY | AJINOMOTO CO., INC. (JP) | 2007-12-20 | — | — | US | disclosed |
| EP-1829968-A1 | MUTANT PROTEIN HAVING PEPTIDE-PRODUCTION ACTIVITY | Ajinomoto Co., Inc. (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-20070190602-A1 | Mutant protein having the peptide-synthesizing activity | AJINOMOTO CO., INC (JP) | 2007-08-16 | — | — | US | disclosed |
| US-20060188976-A1 | Mutant protein having the peptide-synthesizing activity | AJINOMOTO CO. INC (JP) | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085050-A1 | TRIPLE KINASE INHIBITORS | ALK, ERBB2, ERBB3 | CTSC 450/4885MEN1 1645/4885KMT2A 1003/4885 |
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | CTSC 131/4885MEN1 1217/4885KMT2A 1801/4885 |
| US-20250262216-A1 | THERAPEUTIC USES OF MACROCYCLIC COMPOUNDS | VHL, GLS, DLD | CTSC 764/4885MEN1 633/4885KMT2A 3972/4885 |
| US-20260028320-A1 | REAGENTS AND METHODS FOR BIOORTHOGONAL LABELING OF BIOMOLECULES IN LIVING CELLS | TET1, TET3, PTMS | CTSC 1556/4885MEN1 2257/4885KMT2A 671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.